EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Factors implicated in underutilization and poor persistence with hypomethylating agent therapy in myelodysplastic syndromes and chronic myelomonocytic leukaemia in Pakistan

Zoya Ziad, Aisha Arshad, Laraib Majeed, Muhammad Nizamuddin, Aisha Jamal, Quratulain Rizvi, Nida Anwar

Journal of the Pakistan Medical Association · 25.06.2026 · 76 (07) · 1061-1068

DOI: 10.47391/jpma.22820 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Journal of the Pakistan Medical Association, online erschienen am 25.06.2026. Verfasst von Zoya Ziad und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Haematology, National Institute of Blood Diseases and Bone Marrow Transplantation, Karachi, Pakistan. Hauptthemen laut MEDLINE: Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic, Antimetabolites, Antineoplastic, Drug Monitoring. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To assess the clinical and non-clinical factors leading to non-compliance or discontinuation of hypomethylating agent therapy in patients of myelodysplastic syndromes and chronic myelomonocytic leukaemia.

Method

The prospective, observational, cohort study was conducted at the National Institute of Blood Diseases and Bone Marrow Transplantation, Karachi, from January 2022 to January 2024, and comprised patients diagnosed with myelodysplastic syndromes or chronic myelomonocytic leukaemia who were started on a monthly cycle of hypomethylating agent therapy, but either discontinued treatment or suffered from treatment interruption of 60 days or more. Demographics and clinical data was collected from the medical records and a questionnaire-based survey via direct interview with the patients. Data was analysed using SPSS 25.

Results

Of the 39 patients with median age 60 years (interquartile range: 53-70 years), 25(64.1%) were male, 23(59%) had myelodysplastic syndromes, and 16(41%) had chronic myelomonocytic leukaemia. The median number of hypomethylating agent cycles received was 3 (interquartile range: 01-11). Common clinical factors influencing poor persistence to therapy included comorbidities 16(41.0%) and infections 15(38.4%). Among the non-clinical factors, affordability, patients’ perception of disease, weak family support, and drug unavailability were commonly associated with non-persistence to therapy, with treatment affordability showing a statistically significant association (p=0.037).

Conclusion

The factors leading to poor compliance related to hypomethylating agent therapy among patients with myelodysplastic syndromes and chronic myelomonocytic leukaemia could be predicted beforehand and addressed to a certain degree through collaborative efforts. Key Words: Myelodysplastic syndromes, Chronic myelomonocytic leukaemia, Hypomethylating agents.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myelodysplastic SyndromesLeukemia, Myelomonocytic, ChronicAntimetabolites, AntineoplasticDrug MonitoringHumansMiddle AgedPakistanMaleFemaleProspective StudiesAgedUndertreatmentAzacitidineDecitabine

Stichwörter der Autor:innen

Myelodysplastic syndromes, Chronic myelomonocytic leukaemia, Hypomethylating ag…

Substanzen

Antimetabolites, AntineoplasticAzacitidineDecitabine

Autor:innen und Institutionen

  • Department of Clinical Haematology, National Institute of Blood Diseases and Bone Marrow Transplantation, Karachi, Pakistan.
  • Department of Research and Development, National Institute of Blood Diseases and Bone Marrow Transplantation, Karachi, Pakistan.

Zitieren

APA

Ziad, Z., Arshad, A., Majeed, L., Nizamuddin, M., Jamal, A., Rizvi, Q., & Anwar, N. (2026). Factors implicated in underutilization and poor persistence with hypomethylating agent therapy in myelodysplastic syndromes and chronic myelomonocytic leukaemia in Pakistan. Journal of the Pakistan Medical Association, 76(07), 1061-1068. https://doi.org/10.47391/jpma.22820

Vancouver

Ziad Z, Arshad A, Majeed L, Nizamuddin M, Jamal A, Rizvi Q, et al. Factors implicated in underutilization and poor persistence with hypomethylating agent therapy in myelodysplastic syndromes and chronic myelomonocytic leukaemia in Pakistan. Journal of the Pakistan Medical Association. 2026;76(07):1061-1068. doi:10.47391/jpma.22820

BibTeX
@article{Ziad2026,
  author = {Ziad, Zoya and Arshad, Aisha and Majeed, Laraib and Nizamuddin, Muhammad and Jamal, Aisha and Rizvi, Quratulain and Anwar, Nida},
  title = {Factors implicated in underutilization and poor persistence with hypomethylating agent therapy in myelodysplastic syndromes and chronic myelomonocytic leukaemia in Pakistan},
  journal = {Journal of the Pakistan Medical Association},
  year = {2026},
  volume = {76},
  number = {07},
  pages = {1061--1068},
  doi = {10.47391/jpma.22820}
}
Kostenlos starten →